Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with ...

In a report released on April 9, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly and ...

Eli Lilly’s stock took a 4.6% dive after Morgan Stanley gently tapped the brakes on its optimism, lowering its price target ...

The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U.S. imposed ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to ...

Eli Lilly is reaping the benefits from its innovation in diabetes and obesity management, with therapies like Mounjaro and ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of ...